| Literature DB >> 34012916 |
Zhiqiang Chen1, Bingran Yu1, Jiaping Bai2, Qiong Li1, Bowen Xu1, Zhaoru Dong1, Xuting Zhi1, Tao Li1.
Abstract
BACKGROUND: Intraoperative frozen section (FS) is broadly used during pancreaticoduodenectomy (PD) to ensure a negative margin status, but its survival benefits on obtaining a secondary R0 resection for distal cholangiocarcinoma (dCCA) is controversial and unclear.Entities:
Keywords: distal cholangiocarcinoma; frozen section; pancreatoduodenectomy; resection margin; survival analysis
Year: 2021 PMID: 34012916 PMCID: PMC8127005 DOI: 10.3389/fonc.2021.650585
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Flow chart of patient selection and classification of the study. 107 patients were included and divided into different groups based on use of FS (FS and non-FS groups) and resection margin status (pR0, sR0 and R1 groups).
Patient demographics and clinicopathologic characteristics.
| Total (N = 107) | Subgroups by FS | Subgroups by resection margin status | ||||||
|---|---|---|---|---|---|---|---|---|
| non-FS group (n = 57) | FS group (n = 50) |
| pR0 group (n = 88) | sR0 group (n = 10) | R1 group (n = 9) |
| ||
| Age (mean ± SD, years) | 62.3 ± 8.21 | 62.0 ± 8.46 | 62.7 ± 7.96 | 0.637 | 62.2 ± 8.14 | 60.5 ± 9.55 | 65.6 ± 7.32 | 0.388 |
| Sex | 0.486 | 0.106 | ||||||
| Male | 70 (65.4%) | 39 (68.4%) | 31 (62.0%) | 60 (68.2%) | 7 (70.0%) | 3 (33.3%) | ||
| Female | 37 (34.6%) | 18 (31.6%) | 19 (38.0%) | 28 (31.8%) | 3 (30.0%) | 6 (66.7%) | ||
| Complication | 40 (37.4%) | 23 (40.4%) | 17 (34.0%) | 0.498 | 33 (37.5%) | 4 (40.0%) | 3 (33.3%) | 0.955 |
| CA199 (mean, U/ml) | 242.1 ± 297.44 | 255.0 ± 317.86 | 227.3 ± 274.78 | 0.634 | 233.9 ± 295.41 | 167.8 ± 150.86 | 404.0 ± 400.64 | 0.188 |
| Pre-operative biliary drainage | 64 (90.1%) | 37 (64.9%) | 34 (68.0%) | 0.736 | 58 (65.9%) | 9 (90.0%) | 4 (44.4%) | 0.108 |
| Pancreatoduodenectomy | 100 (93.5%) | 53 (93.0%) | 47 (94.0%) | 0.832 | 83 (94.3%) | 9 (90.0%) | 8 (88.9%) | 0.737 |
| Clavien-Dindo classification | 0.841 | 0.522 | ||||||
| I | 61 (57.0%) | 31 (54.4%) | 30 (60.0%) | 51 (58.0%) | 5 (50.0%) | 5 (55.6%) | ||
| II | 14 (13.1%) | 8 (14.0%) | 6 (12.0%) | 13 (14.8%) | 0 (0%) | 1 (11.1%) | ||
| III | 32 (29.9%) | 18 (31.6%) | 14 (28.0%) | 24 (27.3%) | 5 (50.0%) | 3 (33.3%) | ||
| Tumor differentiation | 0.299 | 0.723 | ||||||
| Low | 46 (43.0%) | 22 (38.6%) | 24 (48.0%) | 39 (44.3%) | 4 (40.0%) | 3 (33.3%) | ||
| Moderate | 51 (47.7%) | 31 (54.4%) | 20 (40.0%) | 42 (47.7%) | 5 (50.0%) | 4 (44.4%) | ||
| High | 10 (9.3%) | 4 (7.0%) | 6 (12.0%) | 7 (8.0%) | 1 (10.0%) | 2 (22.2%) | ||
| Tumor size (mean, cm) | 2.0±0.66 | 1.9±0.81 | 2.0±0.82 | 0.846 | 1.9±0.76 | 2.4±1.23 | 2.1±0.67 | 0.182 |
| T stage | 0.808 | 0.985 | ||||||
| T1/2 | 33 (30.8%) | 17 (29.8%) | 16 (32.0%) | 27 (30.7%) | 3 (30.0%) | 3 (33.3%) | ||
| T3 | 74 (69.2%) | 40 (70.2%) | 34 (68.0%) | 61 (69.3%) | 7 (70.0%) | 6 (66.7%) | ||
| Pancreatic invasion | 67 (62.6%) | 37 (64.9%) | 30 (60.0%) | 0.600 | 54 (61.4%) | 6 (60.0%) | 7 (77.8%) | 0.615 |
| Duodenal invasion | 17 (15.9%) | 12 (21.1%) | 5 (10.0%) | 0.119 | 15 (17.0%) | 1 (10.0%) | 1 (11.1%) | 0.778 |
| Microvascular invasion | 20 (18.7%) | 11 (19.3%) | 9 (18.0%) | 0.864 | 18 (20.5%) | 1 (10.0%) | 1 (11.1%) | 0.601 |
| Lymph invasion | 24 (22.4%) | 12 (21.1%) | 12 (24.0%) | 0.715 | 21 (23.9%) | 1 (10.0%) | 2 (22.2%) | 0.609 |
| Perineural invasion | 36 (33.6%) | 19 (33.3%) | 17 (34.0%) | 0.942 | 29 (33.0%) | 5 (50.0%) | 2 (22.2%) | 0.418 |
| Adjuvant treatment | 33 (30.8%) | 19 (33.3%) | 14 (28.0%) | 0.551 | 23 (26.1%) | 5 (50.0%) | 5 (55.6%) | 0.074 |
Figure 2Survival analysis between FS (n = 50) and non-FS (n = 57) groups showed no statistical difference.
Figure 3Survival analysis between R0 (n = 98) and R1 (n = 9) groups showed a better survival of R0 resection with a statistically significant difference.
Figure 4Subgroups analyses of the overall survival between pR0 (n = 88), sR0 (n = 10) and R1 (n = 9) groups showed a significant better survival for pR0 group of patients, but no statistical differences between sR0 vs. pR0 and sR0 vs. R1.
Multivariate analysis of variables associated with overall survival.
| Variable | Median survival (months) | 5-year survival (%) | Hazard ratio | 95% CI |
|
|---|---|---|---|---|---|
| Sex | 0.066 | ||||
| Male | 28 | 38.0 | 1.00 (reference) | ||
| Female | 26 | 7.9 | 1.70 | 0.965–2.985 | |
| Biliary drainage | 0.033 | ||||
| No | 29 | 37.4 | 1.00 (reference) | ||
| Yes | 25 | 13.2 | 1.94 | 1.056–3.580 | |
| Clavien-Dindo classification | 0.101 | ||||
| I | 29 | 24.3 | 1.00 (reference) | ||
| II | 53 | 25.5 | 0.69 | 0.265–1.794 | |
| III | 25 | 18.2 | 1.63 | 0.917–2.889 | |
| Lymph invasion | 0.017 | ||||
| Negative | 29 | 26.2 | 1.00 (reference) | ||
| Positive | 20 | 0 | 2.21 | 1.151–4.255 | |
| Margin status | 0.010 | ||||
| pR0 | 29 | 29.1 | 1.00 (reference) | ||
| sR0 | 25 | 0 | 1.089 | 0.438–2.705 | 0.854 |
| R1 | 22 | 0 | 3.233 | 1.517–6.890 | 0.002 |